A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Latest Information Update: 01 Sep 2022
At a glance
- Drugs Dociparstat sodium (Primary)
- Indications Acute lung injury; COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Chimerix
- 24 May 2021 Status changed from recruiting to discontinued.
- 26 Feb 2021 According to a Chimerix media release, 12 patients has been enrolled in second cohort and will update topline data from this second cohort in the second quarter.
- 25 Feb 2021 According to a Chimerix media release, the second cohort of 12 patients, which is randomized 2:1 and explores a higher dose of DSTAT is now fully enrolled and we look forward to reporting topline data from this cohort in the second quarter.